On December 10, 2020 Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T cell enhancing therapeutics, reported that it has expanded its global, multi-target discovery and development collaboration with Takeda Pharmaceutical Company Limited (Takeda) after Crescendo achieved its sixth technical milestone (Press release, Crescendo Biologics, DEC 10, 2020, View Source [SID1234572619]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under its ongoing collaboration and license agreement, Crescendo’s proprietary transgenic platform and engineering expertise is being used to build Humabody-based therapeutics against certain targets selected by Takeda.
The collaboration expansion gives Takeda access to a range of Crescendo’s half-life extension Humabodies for use with its two Humabody programmes, previously licensed in November 2018 and July 2019, and Humabody programmes Takeda licenses in the future during the term of the collaboration expansion.
This is the sixth technical milestone achieved by Crescendo in its collaboration with Takeda. Crescendo has successfully delivered novel oncology-targeted Humabody lead molecules using its robust in-house discovery process.
Theodora Harold, CEO of Crescendo, commented:
"Crescendo has again demonstrated its ability to deliver differentiated Humabody molecules against specific targets selected by Takeda, on schedule. The expansion of our collaboration, together with the achievement of this sixth milestone, further validates the excellent work being done at Crescendo to progress the next generation of differentiated cancer therapies."
Loïc Vincent, Head, Oncology Drug Discovery Unit, Takeda, commented:
"Our fruitful collaboration with Crescendo continues to show great progress. We are delighted to expand our work together, drawing on Takeda’s vast oncology drug discovery experience and Crescendo’s expertise in developing optimally constructed Humabody molecules to quickly advance novel therapeutics with transformative treatment potential towards the clinic."